Alicja Urbaniak: Targeting CD148 to Develop New Antithrombotic Therapies
Alicja Urbaniak, Instructor at UAMS – University of Arkansas for Medical Sciences, Full Member Cancer Therapeutics Program at The Winthrop P. Rockefeller Cancer Institute at UAMS, Chair of the Partnerships Committee at American Society for Pharmacology and Experimental Therapeutics – ASPET, shared a post on LinkedIn about a recent article by Lina El Badaoui et al., published in Pharmacology Research and Perspectives, adding:
“The article ‘Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB-9778,’ recently published in Pharmacology Research and Perspectives, explores AKB-9778 (razuprotafib) and its potential to inhibit CD148, a protein tyrosine phosphatase involved in platelet activation.
AKB-9778 partially inhibited thrombus formation in an in vitro whole-blood model. Molecular docking and mutagenesis helped identify residues involved in its interaction with CD148.
However, its potency against CD148 was substantially lower than previously reported, highlighting the need for further characterization and optimization.
These findings suggest that AKB-9778 could serve as a starting point for developing more selective and effective CD148 inhibitors.
While this early-stage research offers a promising direction for antithrombotic drug discovery, clinical efficacy and the potential for a lower bleeding risk remain to be established.”
Title: Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB-9778
Authors: Lina El Badaoui, Stipo Jurcevic, Yotis A. Senis, Alastair J. Barr

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series